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Arab American immigrants are an understudied minority in the United States due to their 
invisibility under the White racial group in census data. As such, there is little health research 
regarding their preventative behaviors, including for cervical cancer, a preventable but fatal 
illness. Human papillomavirus infection (HPV), a sexually-transmitted infection which can be 
prevented through the administration of a 3 regimen vaccine between the ages of 9 and 26 is 
the primary known cause. This study assesses the relationship between region of birth and HPV 
vaccination. 
Methods 
Utilizing data from the National Health Interview Survey (NHIS) from 2016, 2017, and 2018, we 
assessed the relationship between region of birth and HPV vaccination. The primary outcomes 
of interest were ever having received the vaccine, how many shots of the vaccine were 
received, and at what age the first shot of the vaccine was received. The demographic variables 
of interest, or covariates, were age, education level, years spent in the US, marital status, 
health insurance coverage, and employment status. A frequency analysis was conducted for all 
variables of interest and odds ratios were calculated for the primary outcomes of interest after 
controlling for covariates. 
Results 
Arab Americans had a lower odds (OR = 0.435) of ever having received the HPV vaccine 
compared with participants born in the US than those born in Europe or Other regions. Further, 
Arab Americans had a lower odds (OR = 0.122) of completing the 3-shot vaccine regimen as 
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well. Not a single Arab American participant reported receiving the first shot on time (below the 
age of 15). Due to a lack of data, the latter two outcomes were not statistically significant. 
Conclusions 
Overall, the Arab American minority has a significantly lower odds of ever having received the 
HPV vaccine than their White counterparts and a lower odds of completing the vaccine regimen 
or receiving the first shot of the vaccine on time. This study validates the existence of health 
disparities and exemplifies the need for more research targeted towards this minority group. 
Key Words: HPV, cervical cancer, vaccine, Arab American 
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As any minority group in the United States, specifically immigrant group, Arab 
Americans face unique sociocultural barriers to receiving healthcare and participating in 
preventative health behaviors (Dallo & Kindratt, 2015; Echeverria & Carrasquillo, 2006; Singh & 
Hiatt, 2006). However, unlike many other minority groups, Arab Americans are not as 
thoroughly studied in preventative health literature, or even health literature more generally 
(Abboud et al., 2017). A primary cause for this discrepancy in a lack of health knowledge is the 
categorization of Arab Americans as “White” in the overwhelming majority of census data 
(Abboud et al., 2017). This phenomenon tends to make the Arab American minority invisible in 
research documenting health disparities among racial and ethnic cohorts. 
One of the understudied health disparities among Arab American women is cervical 
cancer, particularly prevention (Abboud et al., 2017). Cervical cancer is a particular concern 
because Arab American women have a screening rate of 87% at best which still falls below the 
Healthy People 2020 target of 93% screening (Dallo & Kindratt, 2015). With inadequate rates of 
screening, prevention is that much more important. Cervical cancer is one of the only cancers 
with a known primary cause, HPV infection (F X Bosch, Lorincz, Muñoz, Meijer, & Shah, 2002; 
Klingelhutz & Roman, 2012; Muñoz, Castellsagué, de González, & Gissmann, 2006; Nour, 2009). 
Cervical cancer is an aggressive disease once it takes hold of the human body, often detected in 
advanced stages when women typically become symptomatic (Castle et al., 2009; Klingelhutz & 
Roman, 2012; Lewis et al., 2010). Like most other cancers, the cells in the lining of the outer 
part of the cervix or in the column-shaped glandular cells that line the cervical canal, mutate to 
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override apoptosis, or programmed cell death, and multiply without control (F X Bosch et al., 
2002; Klingelhutz & Roman, 2012; Lewis et al., 2010). Eventually, this cluster of accumulated 
out-of-control cells forms a mass, or tumor, which can break off and invade nearby tissue, 
metastasizing in other parts of the body (F X Bosch et al., 2002; Klingelhutz & Roman, 2012; 
Lewis et al., 2010). 
Human Papillomavirus 
HPV infection is the primary cause of cervical cancer (F. Xavier Bosch et al., 1995; Burd & 
Dean, 2016). Human papillomavirus consists of 19 well-known strains, all of which carry varying 
amounts of risk for the host (Burd & Dean, 2016; Castle et al., 2009). Of these 19 strains, 
approximately 12 are classified as high risk by the International Agency for Research on Cancer, 
such that the gene expression of HPV becomes deregulated and their abnormal life cycle is 
associated with progression to cancer (Burd & Dean, 2016; Castle et al., 2009; Lewis et al., 
2010; Muñoz et al., 2003; Muñoz et al., 2006). HPV strains 16 and 18 are particularly identified 
as carcinogenic as they are cited to cause the majority of HPV-related cancers, including 
cervical, anal, vaginal, oropharyngeal, and more (Lewis et al., 2010; Muñoz et al., 2003). 
HPV is a deadly virus that can result in viral infection in the host as a result of several risk 
factors, including sexual relations with multiple partners, unprotected sex, smoking, lack of 
access to vaccination and screening, and more (F X Bosch et al., 2002; Jain et al., 2009; 
Walboomers et al., 1999). HPV is the single most common sexually transmitted infection 
globally (F. Xavier Bosch et al., 1995). 
HPV can be transmitted fairly easily through simple skin-to-skin sexual contact, including 
genital and oral (Münger et al., 2004; Muñoz et al., 2006). Further, multiple strains of HPV can 
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infect an individual at any given time (Münger et al., 2004; Muñoz et al., 2006). While most 
sexually active individuals will contract HPV at some point in their lives, particularly if they are 
subject to or participate in common risk factors, infection will only become cancerous in less 
than 10% of individuals (Klingelhutz & Roman, 2012; Nour, 2009). Interestingly, this still 
constitutes a large number of people as cervical cancer and other cancers attributed to HPV are 
the 4th leading cause of death in women worldwide (F X Bosch et al., 2002; F. Xavier Bosch et 
al., 1995; Castle et al., 2009). 
In 50% of cases of HPV infection, the host immune system is able to attack and manage 
the virus before it leads to carcinoma within one year (F X Bosch et al., 2002; Castle et al., 
2009). In 90% of cases, this occurs within two years (F X Bosch et al., 2002; Castle et al., 2009). 
However, in individuals with weakened immune systems or as a result of other sociocultural or 
environmental factors, this attack is not always possible or successful, resulting in persistent 
infection for years or decades which ultimately results in cancer (Castle et al., 2009; Khan et al., 
2005; Klingelhutz & Roman, 2012). HPV, although not sufficient, is a necessary factor for the 
development of cervical cancer. 
Cervical Cancer Prevention 
While the onset of cervical cancer in its early-stages does not typically boast drastic 
symptoms, more advanced cervical cancer can be identified through excessive vaginal bleeding 
after intercourse or between periods or after menopause, watery and bloody vaginal discharge 
which may be heavy accompanied with a foul odor, and pelvic pain or abnormal pain during 
intercourse (Moyer & Force*, 2012; Nour, 2009; Walboomers et al., 1999). When these 
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symptoms arise, it is often at a stage where cervical cancer is difficult to manage and treat 
(Nour, 2009). As such, while preventable, cervical cancer is a silent killer. 
Fortunately, despite the potentially fatal outcome of certain high-risk HPV infection, this 
virus is preventable through vaccination (Burd & Dean, 2016; Zhai & Tumban, 2016). The most 
recent, and most commonly utilized, vaccine is Gardasil-9 which is known to protect against 9 
strains of HPV, including high and low risk strains (Zhai & Tumban, 2016). This vaccine can be 
administered in young women and girls as early as the age of 9 (Zhai & Tumban, 2016). 
However, Gardasil-9 does not protect against HPV infection as effectively if an individual as 
already been exposed to or contracted HPV ("Advisory Committee on Immunization Practices 
(ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory 
Committee on Immunization Practices (ACIP)," 2019; Zhai & Tumban, 2016). As such, health 
professionals recommend administering the vaccine to adolescent girls before sexual activity 
begins ("Advisory Committee on Immunization Practices (ACIP). Quadrivalent human 
papillomavirus vaccine: recommendations of the Advisory Committee on Immunization 
Practices (ACIP)," 2019). According to the Centers for Disease Control and Prevention (CDC), 
which cuts off “late” at age 15 after which 3 shots are necessary for complete vaccination, the 
ideal age to begin the vaccine regimen is ages 11-12 ("Advisory Committee on Immunization 
Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory 
Committee on Immunization Practices (ACIP)," 2019). While 13-14 is technically late, age 15 is 
beyond the grace period ("Advisory Committee on Immunization Practices (ACIP). Quadrivalent 
human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization 
Practices (ACIP)," 2019). 
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Further, Gardasil-9 is an intramuscular vaccine which must be administered in a series of 
three injections over the course of 6 months, requiring repeated access to a healthcare facility, 
providers, and the appropriate resources (Zhai & Tumban, 2016). Once vaccinated, an 
individual can be effectively protected from HPV infection for up to 10 years (Franceschi et al., 
2006; Khan et al., 2005). However, as any vaccination is not 100% effective, this alone is an 
imperfect method of HPV prevention. As such, routine screening for both HPV and cervical 
cancer is recommended in women starting at age 21 throughout their reproductive life and 
even after menopause (Abboud et al., 2017; Moyer & Force*, 2012). 
Purpose 
Cervical cancer largely affects women aged 30-50 which are arguably the most 
productive years of one’s life (F. Xavier Bosch et al., 1995; Dallo & Kindratt, 2015; Nour, 2009). 
Cervical cancer, along with its treatments, has been shown to decrease quality of life in 
survivors and continue to cause adverse health outcomes such as changes in sexual and urinary 
comfort, fertility, and mental health (Abboud et al., 2017; Nour, 2009). Although rates of 
cervical cancer incidence have been slowly declining aby approximately 1% annually over the 
past two decades, rates of mortality attributed to cervical cancer have remained stoic, 
disproportionately affecting racial and ethnic minorities which has been well documented for 
Black women, Native American women, and Hispanic women (Abboud et al., 2017). These 
disparities seem to be related to several intersecting factors such as ethnicity and race, 
socioeconomic status, access to insurance, and nativity, just to name a few (Abboud et al., 
2017; Dallo & Kindratt, 2015). 
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The United States is witnessing a growing ethnic minority of Arab Americans with 
Middle Eastern nativity (Echeverria & Carrasquillo, 2006; El-Sayed & Galea, 2009). However, 
health-seeking behaviors and preventative medicine have been largely understudied in this 
population due to their classification as White in census data collected by governmental 
agencies (Ajrouch & Jamal, 2007). This erasure has primarily been perpetuated by two 
sociopolitical factors. First, many Arab Americans, upon arrival to the United States in the late 
twentieth century and early twenty-first century, actively pursued the White categorization as a 
form of assimilation and belonging (Ajrouch & Jamal, 2007; Dallo, Booza, & Nguyen, 2015). 
Second, after the terrorist attack on September 11th, 2001, which dramatically heightened 
racism and fear targeted at Arab Americans and Muslims more generally, this invisibility in 
research and data collection adversely contributed to a lack of understanding of their health 
behaviors and access to care which were negatively impacted in the face of discrimination 
(Abu-Ras & Abu-Bader, 2008, 2009; Dallo et al., 2018; Echeverria & Carrasquillo, 2006; El-Sayed 
& Galea, 2009; Hassouneh & Kulwicki, 2007; Jamal A, 2008). 
As such, only studies which actively seek out data on the Arab American immigrant 
population specifically are able to assess their health disparities compared with their White 
counterparts (Abboud et al., 2017; Dallo et al., 2015; Dallo & Kindratt, 2015; El-Sayed & Galea, 
2009). This lack of research calls for a better understanding of health outcomes within this 
population. The discrimination has only serve to worsen both their mental and physical health 
and their ability to access appropriate and timely care without stigma or other sociocultural and 
political barriers (Abu-Ras & Abu-Bader, 2008, 2009; Echeverria & Carrasquillo, 2006; 
Hassouneh & Kulwicki, 2007). In order to address this problem, this study aims to examine HPV 
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This study aims to assess health disparities in cervical cancer prevention through the 
proxy of HPV vaccination in Arab American immigrant women in the United States compared 
with White women, including White women born in the United States, born in Europe, or born 
elsewhere. In order to do so, three primary variables of interest are assessed: ever having 
received the vaccine, how many shots of the vaccine were received, and at what age the first 
shot of the vaccine was received. 
Statistical Plan 
The primary researcher utilized data from the National Health Interview Survey (NHIS) 
collected by the U.S. Census Bureau, from data releases from the years 2016, 2017, and 2018 to 
conduct a secondary analysis. In summary, this is a national level database that collects cross-
sectional data over the course of a year with the aim of producing a racially/ethnically 
representative sample. Due to sampling methods and time of day the survey is conducted, 
older individuals tend to be oversampled. Details of the NHIS, its sampling design and methods, 
and specific health topics collected were reported previously (National Center for Health 
Statistics, 2012a). The primary researcher combined the “Persons” dataset and “Sample Adult” 
dataset to obtain demographic and health data of interest. The dataset was subset by sex, age, 
and race to only include White females aged 21-65. This subset allows inclusion of all women 
eligible for a routine pap smear, or cervical cancer screening test, every three years and thus, at 
the age of risk for cervical cancer. As this study aims to assess cervical cancer prevention 
through HPV vaccination, this is the population of interest. Ultimately, we assessed 12 variables 
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of interest: "REGIONBR", “MRACBPI2.x”, “SEX”, "AGE_P.x", "EDUC1", "YRSINUS", "R_MARITL.x", 
"COVER", “DOINGLWA", "SHTHPV2", "SHPVDOSP", "AHPVAGE".  
These variables correlate to the following demographic and health information: region 
of birth, race, sex, age, education level, years spent in US, marital status, health insurance 
coverage, employment status, if the woman has ever received an HPV vaccine, the number of 
HPV shots she received, and the age at which she received her first shot. These demographic 
characteristics have been shown in the literature as confounding variables that must be 
controlled for when studying HPV vaccination as an indicator for cervical cancer prevention. 
In terms of analysis, the region of birth variable was recoded to isolate women born in 
the US, Europe, and Middle East as unique categories. All other individuals who identified as 
racially White and in any other region of birth were categorized as “Other”. Of the 24,094 
individuals included in the final dataset, after the data was subset for sex, age, and race, there 
were only 115 individuals that identified the Middle East as their region of birth. In each of the 
tables, descriptive statistics were compared for US, Europe, Middle East, and Other through a 
frequency analysis using the chi-squared statistic for significance. Odds ratios with 
accompanying 95% confidence intervals (CI) for the health outcomes of interest – ever having 
received an HPV vaccine, the number of HPV shots received, and the age at first shot – were 
calculated for Europe, Middle East, and Other utilizing the US as a reference group. We 
controlled for covariates, which in this case were the demographic characteristics of interest 




The final data utilized in this study, from the NHIS years 2016-2018, included women 
racially categorized as White, aged 21-65. As such, 24094 participants were included. Of these 
24094 participants, 21580 recorded United States as their region of birth, 497 recorded Europe 
as their region of birth, and only 115 recorded the Middle East as their region of birth. Another 
1902 recorded various other geographic regions, including Russia, Central America, and South 
America as their region of birth and were categorized as “Other”. 
 Out of all of the study participants who were women aged 21-65 (n = 32245) but not 
restricted to any particular racial category, 119 women recorded the Middle East as their region 
of birth. As such, there were 4 women who recorded the Middle East as their region of birth but 
did not categorize themselves as White racially. These women were excluded from further 
analyses due to the primary purpose of this study to assess health disparities among Arab 




After conducting frequency analyses of the demographic and health information of 
interest against region of birth, we obtained Tables 1 and 2. 
Table 1: Demographic Information of Sample Adult Against Region of Birth – Subset to Female, 
White, Aged 21-65* 
Characteristic 






(n = 21580) 
Europe 
(n = 497) 
Middle 
East 
(n = 115) 
Other 
(n = 1902) 
Age (years), mean ± SD 44.8 ± 13.2 47.0 ± 11.7 43.6 ± 12.3 43.1 ± 12.0 <0.001 
Year(s) Spent in the 
United States, n (%) 
    
<0.001 
     <5 NA 39 (7.9) 28 (24.3) 185 (10.0)  
     5-10 NA 22 (4.5) 19 (16.5) 162 (8.7)  
     10-15 NA 44 (8.9) 6 (5.2) 243 (13.1)  
     >15 NA 387 (78.7) 62 (53.9) 1269 (68.3)  
Education, n (%)     <0.001 
     Less than high school 1258 (6.4) 22 (4.8) 10 (8.9) 548 (30.5)  
     High school graduate 4334 (22.1) 90 (19.8) 17 (15.2) 400 (22.3)  
     Some college 5346 (27.2) 99 (21.8) 21 (18.8) 282 (15.7)  
     Bachelor or higher 8686 (44.3) 243 (53.5) 64 (57.1) 565 (31.5)  
Marital status, n (%)     <0.001 
     Married 10930 (50.7) 274 (55.2) 78 (67.8) 1033 (54.5)  
    Widowed/Sep/Divorced 4873 (18.7) 67 (13.5) 19 (16.5) 414 (21.8)  
     Living with partner 1719 (8.0) 29 (5.8) 0 (0.0) 133 (7.0)  
     Never married 4025 (18.7) 126 (25.4) 18 (15.7) 317 (16.7)  
Health Insurance, n (%)     <0.001 
     Private 15420 (73.8) 360 (75.2) 72 (63.7) 929 (50.3)  
     Medicaid, Other public 2690 (12.8) 44 (9.2) 18 (15.9) 317 (17.2)  
     Other coverage 1101 (5.3) 39 (8.1) 5 (4.4) 80 (4.3)  
     Uninsured 1700 (8.1) 36 (7.5) 18 (15.9) 520 (28.2)  
Employment Status, n (%)     <0.001 
     Working for pay 14996 (69.5) 340 (68.4) 57 (49.6) 1145 (60.2)  
     Looking for work 575 (2.7) 15 (3.0) 6 (5.2) 68 (3.6)  
     Not working for pay 6003 (27.8) 142 (28.6) 52 (45.2) 688 (36.2)  
* Numbers may not sum to totals due to missing data, and column percentages may not sum to 
100% due to rounding. 
 
This table compares the unadjusted associations between region of birth and 
demographic variables (n = 24094). There was a statistically significant relationship between 
age and region of birth such that European-born participants had the oldest average age at 
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approximately 47 years while Middle Eastern-born participants and participants born in Other 
regions had the youngest average age at approximately 43 years.  
Further, there was a statistically significant relationship between region of birth and 
years spent in the United States such that nearly 80% of European-born participants had lived 
in the United States for over 15 years while just over 50% of Middle Eastern-born participants 
had lived in the United States for over 15 years and nearly 25% had lived in the United States 
for less than 5 years. Participants born in the United States were excluded from this measure in 
the original dataset.  
In terms of education, Middle Eastern-born participants were the most highly educated 
group with nearly 60% of participants boasting a bachelor’s degree or higher. Alternatively, 
more than 30% of participants born in Other geographic regions had less than a high school 
education. European-born participants had comparable percentages to Middle Eastern born 
participants such that almost 55% had received a bachelor’s degree or higher followed by the 
United States in which approximately 45% of participants had received a bachelor’s degree or 
higher. 
Further, there was a statistically significant relationship between marital status and 
region of birth such that Middle Eastern-born participants had the highest percentage of 
married women at nearly 70% and the lowest percentage of never married women at around 
15%. Interestingly, not a single one of the 115 participants recorded living with a partner while 
unmarried. United States-born participants, European-born participants, and participants born 
in Other geographic regions had similar percentages of married women at around 50-55% of 
participants. United States-born participants had the highest percentage of women living with a 
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partner while unmarried at 8% and European-born participants had the highest percentage of 
unmarried women at over 25%. 
In terms of health insurance coverage, a majority of US-born participants, European-
born participants, Middle Eastern-born participants, and participants born in Other regions had 
private insurance at approximately 74%, 75%, 64%, and just over 50%, respectively. However, 
Middle Eastern born participants and participants born in Other geographic regions had the 
highest percentage of individuals utilizing Medicaid or another form of public health insurance 
at approximately 16% and 17%, respectively. Further, these two groups had significantly higher 
rates of uninsured participants than their US-born and European-born counterparts at around 
16% and 28%, respectively. 
Finally, in terms of employment, Middle Eastern-born participants had the significantly 
lowest percentage of women working for pay at just below 50% and the highest percentage of 
women not working for pay at approximately 45%. Further, Middle Eastern-born participants 
had the highest percentage of women looking for work out of all the groups at over 5%.  
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Table 2: HPV Vaccination Status – Descriptive Statistics* 
Characteristic 





(n = 21580) 
Europe 
(n = 497) 
Middle East 
(n = 115) 
Other 
(n = 1902) 
Ever received 
HPV Vaccine, n 
(%) 
*(n = 20144)  *(n = 456) *(n = 100) *(n = 1739) 
 
<0.001 
     Yes 2630 (13.1) 32 (7.0) 6 (6.0) 152 (8.7)  
     No 17514 (86.9) 424 (93.0) 94 (94.0) 1587 (91.3)  
Number of HPV 
shots received, n 
(%) 
*(n = 2315)  *(n = 28) *(n = 5) *(n = 129) 
 
0.042 
     1 410 (17.7) 8 (28.6) 4 (80.0) 37 (28.7)  
     2 348 (15.0) 5 (17.9) 0 (0.0) 20 (15.5)  
     All 1557 (67.3) 15 (53.6) 1 (20.0) 72 (55.8)  
Age at first HPV 
shot (years), 
mean ± SD 
18.7 ± 6.5 21.4 ± 8.0 19.6 ± 5.0 21.2 ± 7.7 
 
0.381 
* Numbers may not sum to totals due to missing data, and column percentages may not sum to 
100% due to rounding. 
 
This table compares the unadjusted associations between region of birth and health 
outcomes of interest (n = 24094). There was a statistically significant relationship between ever 
having received and HPV vaccine and region of birth such that United States-born participants 
had the highest percentage of women who had ever received the vaccine at approximately 13% 
while Middle Eastern-born participants had the lowest percentage at 6%.  
Further, Middle Eastern-born participants had a significantly lower percentage of 
women who had completed the HPV vaccine regimen at just 20% compared with their White 
counterparts at approximately 67%, 54%, and 56% for United States-born participants, 
European-born participants, and participants born in Other regions, respectively. None of the 
Middle Eastern-born participants had received two shots and 80% had received just one.  
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Notably, there is a small sample size for this data such that of the 6 Middle Eastern-born 
individuals who reported receiving the vaccine, only 5 indicated the number of shots they 
received and the age at their first shot. Similarly, only 2315 out of the 2630 United-States born 
participants that reported receiving a vaccine also reported how many shots and age at first 
shot. This is true for European-born participants and participants born in Other regions at 28 
out of 32 and 129 out of 152 participants, respectively. These small sample sizes compromise 
the significance and generalizability of this data. 
Finally, the average age at which participants received their first HPV shot was not 
statistically different across different geographic regions of birth with United States-born 
participants having an average age of approximately 19, Middle Eastern-born participants 
having an average age of approximately 20, and European-born participants and participants 
from Other regions having an average age of approximately 21. All of these groups had an 
average age considered late by the CDC which cuts off “late” at age 15. 
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After calculating odds ratios with accompanying 95% CIs of the health information of 
interest against region of birth, we obtained Table 3. 
Table 3: Associations between HPV  Vaccination Status and Region of Birth – United States as 
reference group* 
Characteristic 
OR (95% CI) 
Region of Birth 
Europe 
(n = 456) 
Middle East 
(n = 100) 
Other 
(n = 1739) 
Received HPV 
Vaccine 
0.503 (0.350, 0.722) 0.435 (0.186, 0.971) 0.638 (0.537, 0.757) 
Completed HPV 
Vaccine Regimen 
0.562 (0.266, 1.187) 0.122 (0.014, 1.091) 0.615 (0.430, 0.880) 
First HPV Shot 
Before Age 15 
(Not Late) 
0.436 (0.103, 1.849) NA 0.950 (0.574, 1.567) 
* Numbers may not sum to totals due to missing data, and column percentages may not sum to 
100% due to rounding. 
 
 This table assess the adjusted odds ratios between region of birth and health outcomes 
of interest, controlled for the demographic variables highlighted in Table 1. Middle Eastern-
born participants had the statistically significant lowest odds of ever having received an HPV 
vaccine such that they had 0.435 times the odds of receiving the vaccine of United States-born 
participants. This is lower than European-born participants who had 0.503 times the odds of 
United States-born participants and participants from Other regions who had 0.638 times the 
odds of United States-born participants. 
 Further, while not statistically significant due to the small sample sizes as explained in 
the interpretation for Table 2, Middle Eastern-born participants had the lowest odds of 
completing the HPV vaccine regimen such that they had 0.122 times the odds of completing the 
vaccine regiment of United States-born participants. Participants from Other regions had a 
statistically significant lower odds of completing the vaccine regimen compared with United 
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States-born participants such that they had 0.615 times the odds of completing the vaccine 
regimen. 
 Finally, due to the small sample size, not a single one of the 6 Middle Eastern-born 
participants who reported ever having received the vaccine reported receiving the first HPV 
shot before the age of 15, making it impossible to calculate an odds ratio, reported as “NA”. 
Alternatively, although not statistically significant, European-born participants and participants 
born in Other regions had lower odds of receiving the first HPV shot at the age of 15 than 
United States-born participants. While European-born participants were 0.436 had 0.436 times 
the odds of United States-born participants, participants born in Other regions had 0.950 times 
the odds of United States-born participants of receiving the HPV vaccine before the age of 15. 
 Overall, nativity seems to be an indicator of poorer participation in preventative health 
behaviors as indicated by patterns of HPV vaccination. However, these results are limited by 
small sample sizes and as such, are not statistically significant apart from ever having received 





 In the past two decades, tensions and discrimination surrounding the ethnic Arab 
minority in the United States has increased for various reasons including the events of 
September 11, 2001 and the worsening relations between the United States and the Middle 
East as a result of the Iraq war, Trump’s “Muslim ban”, and more (Abu-Ras & Abu-Bader, 2008, 
2009; Echeverria & Carrasquillo, 2006; El-Sayed & Galea, 2009; Hassouneh & Kulwicki, 2007; 
Jamal A, 2008). Consequently, racism has heightened toward Arab American immigrants in the 
United States which has adverse mental and physical effects and can compromise access to 
health benefits, comfort with healthcare providers, and ultimately lead to adverse health 
outcomes (Abu-Ras & Abu-Bader, 2009; Hassouneh & Kulwicki, 2007; Jamal A, 2008). 
 Cervical cancer is a particular concern because Arab American women have a screening 
rate of 87% at best which still falls below the Healthy People 2020 target of 93% screening 
(Dallo, 2015). As such, this paper assessed HPV vaccination among Arab American immigrants in 
the United States compared with their other White counterparts as proxy for cervical cancer 
prevention. 
 This study, which is a secondary analysis of survey data from the National Health 
Interview Survey (NHIS) from the years 2016, 2017, and 2018, includes 24094 participants who 
identified as racially White, female, and between the ages of 21 and 65. Of these 24094 
participants, 21580 recorded United States as their region of birth, 497 recorded Europe as 
their region of birth, and only 115 recorded the Middle East as their region of birth. Another 
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1902 recorded various other geographic regions, including Russia, Central America, and South 
America as their region of birth and were categorized as “Other”. 
 Further, out of all of the study participants who were women aged 21-65 (n = 32245) 
but not restricted to any particular racial category, 119 women recorded the Middle East as 
their region of birth. As such, there were 4 women who recorded the Middle East as their 
region of birth but did not categorize themselves as White racially. These women were 
excluded from further analyses this study primarily aims to assess health disparities among 
Arab American women whose ethnic identity has become invisible by census categorization as 
racially White. 
Demographic Characteristics 
 Overall, the results posit that nativity plays a significant role in education level, marital 
status, health insurance coverage, and employment status, among other variables. Some of the 
most noteworthy results indicated that Middle Eastern-born participants had the highest 
percentage of individuals living in the United states for less than 5 years at 25%. This 
contributes to the existing literature which claims that Arab Americans are one of the fastest 
growing minority groups in the United States today (Dallo et al., 2015; Dallo & Kindratt, 2015; 
Singh & Hiatt, 2006).  
Further, despite being the most highly educated group with nearly 60% of participants 
having a bachelor’s degree or higher, Middle Eastern-born participants had the higher 
percentage of participants looking for work, at approximately 5%. Further, compared to their 
White counterparts, Middle Eastern-born participants had the lowest percentage of women 
working for pay, just below 50%. 
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Further, Middle Eastern-born participants had the highest percentage of married 
women at nearly 70% and the lowest percentage of never married women at around 15%. 
Interestingly, not a single one of the 115 participants recorded living with a partner while 
unmarried. While not explicitly assessed through this study, previous literature shows a more 
conservative culture among Arab Americans with regard to sexual activity which is further 
supported by this statistic (Abboud, Jemmott, & Sommers, 2015; P, 2008). 
Finally, Middle Eastern-born participants did not fare as well their US-born or European-
born counterparts in terms of health insurance coverage such that approximately 16% of 
participants relied on Medicaid or another form of public health insurance rather than private 
insurance and another 16% were uninsured. In contrast, only 8% of US-born and European-born 
participants reported being uninsured. 
Health Outcomes 
The results regarding our health outcomes of interest, ever having received an HPV 
vaccine, number of shots received, and age at first shot, also showed disparities across varying 
regions of birth. There was a statistically significant relationship between ever having received 
and HPV vaccine and region of birth such that United States-born participants had the highest 
percentage of women who had ever received the vaccine at approximately 13% while Middle 
Eastern-born participants had the lowest percentage at just 6%. When adjusted for the 
demographic characteristics outlined in Table 1, Middle Eastern-born participants had the 
statistically significant lowest odds of ever having received an HPV vaccine such that they had 
0.435 times the odds of receiving the vaccine of United States-born participants. This is lower 
than European-born participants who had 0.503 times the odds of United States-born 
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participants and participants from Other regions who had 0.638 times the odds of United 
States-born participants. 
Further, when unadjusted, Middle Eastern-born participants had a significantly lower 
percentage of women who had completed the HPV vaccine regimen at just 20% compared with 
their White counterparts at approximately 67%, 54%, and 56% for United States-born 
participants, European-born participants, and participants born in Other regions, respectively. 
None of the Middle Eastern-born participants had received two shots and 80%, or 4 out of 5, 
had received just one. After adjusting for the demographic variables in Table 1, the odds of 
completing the HPV vaccine were lowest for Middle Easter-born participants such that they had 
0.122 times the odds of completing the vaccine regiment of United States-born participants. 
Finally, while all the groups had similar average ages of receiving the first vaccine, this 
age was above the CDC recommended cut off for receiving the vaccine “late” at age 15. In 
terms of differing odds, due to the small sample size, not a single one of the 6 Middle Eastern-
born participants who reported ever having received the vaccine reported receiving the first 
HPV shot before the age of 15, making it impossible to calculate an odds ratio, as the technical 
odds for receiving the first shot before the age of 15 for United States-born participants are 
infinitely higher than for Middle Eastern-born participants according to this sample. 
Notably, there is a small sample size for this data such that of the 6 Middle Eastern-born 
individuals who reported receiving the vaccine, only 5 indicated the number of shots they 
received and the age at their first shot. Similarly, only 2315 out of the 2630 United-States born 
participants that reported receiving a vaccine also reported how many shots and age at first 
shot. This is true for European-born participants and participants born in Other regions at 28 
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out of 32 and 129 out of 152 participants, respectively. These small sample sizes compromised 
the significance and generalizability of this data overall which in turn affected our ability to 
calculate and interpret odds ratios for the health outcomes of interest. 
Conclusions 
 Ultimately, this study posits that nativity is an indicator of poorer participation in 
preventative health behaviors as indicated by patterns of HPV vaccination. However, these 
results are limited by small sample sizes and as such, are not statistically significant outside of 
ever having received the HPV vaccine. While Arab American women were more highly educated 
than any other category, they had the lowest rates of health insurance coverage and 
employment. While not explicitly assessed in this study, these results hint at social, cultural, 
economic, and political factors which may be affecting access to preventative health care, and 
may be affecting overall health outcomes as a result, within this population. 
Limitations 
Despite the inclusion of three years of data, there are only 115 women included in the 
primary category of interest, Middle East as region of birth. Further, only 100 of these women 
reported any data regarding HPV vaccination status. Similarly, for all other categories of region 
of birth, only a fraction of the participants reported any data regarding HPV vaccination. As 
such, there is very little data at our disposal for the overall assessment of health outcomes 
across these populations which limits our ability to obtain statistical significance in the final 
evaluations. 
Further, this study only assessed cervical cancer prevention through the proxy of HPV 
vaccination status and does not analyze cervical cancer screening and the benefits of early 
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detection on cervical cancer incidence. Due to a lack of health information in the 2016 and 2017 
datasets regarding cervical cancer screening, a more comprehensive assessment of overall 
prevention of cervical cancer mortality was not conducted. 
Finally, due to a lack of data, overall rates of HPV vaccination in the United States among 
Arab Americans generally were not assessed due to a lack of information on ethnicity explicitly. 
Rather, this study was limited to Arab American immigrants specifically as the researchers had 
to utilize Middle Eastern nativity as a proxy for Arab American categorization. 
Future Directions 
 The limited research conducted with this population calls for a better understanding of 
preventative health behaviors among Arab American immigrants. In particular, there needs to 
be more research regarding access to HPV vaccination due to its function as a primary 
contributor to cervical cancer prevention. The purpose of this study is to quantify the disparities 
in access to HPV vaccination among Arab American immigrants with the hope that this research 
may be utilized to inform interventions that bridge the disparities in access to cervical cancer 
prevention through HPV vaccination or even simply identify that these disparities exist to begin 
with, highlighting a gap in health literature. 
 In the future, these questions can also be expanded to individuals with United States 
nativity who ethnically identify as Arab American. Ultimately, this study is not only a call to 
action for more comprehensive and ethnically-inclusive health literature, but also for more 
inclusive categorization in census data and thoughtful assessments of the varying lived 
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